Inflammatory myopathies

Predictors of thrombotic events in patients with idiopathic inflammatory myopathies

Clin Exp RheumatolPublished Retrospective cohort study

Authors' conclusion

We report the incidence and risk factors for thrombotic events in a single-centre longitudinal IIM cohort, showing early occurrence of VTE and late onset of ATE. PON1 activity was predictive of ATE in a high-risk subgroup of IIM patients.

Study context

Population
Patients with idiopathic inflammatory myopathies (IIM) in a large longitudinal cohort followed at a single academic centre
Participants
312 patients
Outcome
Predictors of prospective arterial and venous thrombotic events (ATE and VTE)
Methodological detailssingle-centre, longitudinal cohort, Poisson regression
  • Single-centre
  • Longitudinal cohort
  • Poisson regression

Main finding

As reported in the abstract

median [IQR] follow-up 6[2-11] years
Thrombotic events
37 out of 312 patients (12%)
VTE among patients with thrombotic events (predominantly within first 3 years of IIM diagnosis)
65%
ATE among patients with thrombotic events (predominantly after 10 years from IIM diagnosis)
41%
Disease duration <1 year, strongest risk factor for VTE: IRR
6.49 (1.89-22.35) (95% CI)
Prior ATE, strongest risk factor for prospective ATE: IRR
18.78 (10.98-32.12) (95% CI)

Observational data: associations, not effects.

Further findings

PON1 lactonase activity independent of PON1 Q192R polymorphism; enhanced prediction of ATE in patients with high cardiovascular (CV) risk

Safety

IVIG not associated with increased thrombotic risk in a high-risk population

Original publication

Predictors of thrombotic events in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol. Published 25 November 2024. doi:10.55563/clinexprheumatol/bj7nq2

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.